Patent Landscape and Claim Scope for US Drug Patent 8,961,412: Ingestible Event Marker With “Virtual Dipole” Signal Amplification
US Patent 8,961,412 claims an ingestible “event marker” system in which two opposing signal transmission elements form an actual dipole of a predefined length, with an electrically insulative signal amplification element positioned between them that creates a longer “virtual dipole.” The patent’s core novelty is the dipole-length multiplication concept (virtual dipole larger than actual dipole) implemented with an insulative amplification structure, enabling detection of an emitted signal from an ingestible site when paired with a receiver.
What does US 8,961,412 claim and how broad is the “virtual dipole” concept?
Claim 1 is the independent claim and sets the technical boundary. The key elements are:
- Ingestible event marker
- Identifier configured to emit a signal when it contacts a target site
- Two opposing signal transmission elements producing an actual dipole of predefined dipole length
- Electrically insulative signal amplification element disposed between the transmission elements
- The insulative amplification element produces a virtual dipole with a length larger than the actual dipole
- Downstream configuration optionally includes signal generation element and active agent association (claim 9)
- Optional extension to multiple dipoles (claim 10)
Core inventive feature: insulative amplification creates longer virtual dipole
The insulative amplification element is “configured to produce a virtual dipole having a length defined by the signal amplification element.” This reads like a coupling/field effect approach where an insulative structure influences electrical behavior such that the effective radiating/electrical interaction length is increased without changing the physical spacing between the two opposing transmission elements.
Functional claim scope (what is not limited)
Claim 1 does not, on its face:
- limit the signal type (it says “emit a signal”)
- limit the frequency band/modulation
- require a particular target site other than a “target site fluid present at a target site” in dependent claim 2
- specify whether the amplifier is capacitive, inductive, geometric coupling, or other electromagnetic effect (it only requires insulating and “produces” virtual dipole length)
- require a particular material system for the insulative amplification element
This supports broad coverage around any implementation that satisfies the structural-functional mapping: two electrodes form an actual dipole, and an insulative in-between structure defines a longer effective/virtual dipole length.
Structural claim scope (what is limited)
Claim 1 does impose:
- Opposing spaced relationship between first and second signal transmission elements
- An insulative amplification element disposed between those elements
- The virtual dipole length being larger than actual dipole length
The “length-defined-by” language is likely to be interpreted as tethering the virtual dipole concept to the physical geometry and electrical behavior of the amplification element.
What elements of claim 1 create infringement leverage for competitors?
Competitors that design ingestible sensors/event markers will face infringement risk if they replicate the following “must-have” mappings:
1) Actual dipole length is predefined by two opposing elements
Any device implementing:
- two opposing transmission elements with known/defined separation or effective dipole length
- arranged so that the device’s two-element configuration corresponds to an “actual dipole”
would meet that portion.
2) Virtual dipole is longer and is “defined by” an insulative amplification element
Risk spikes if competitors:
- place an electrically insulative structure between the opposing transmission elements
- use it to create an effective electrical/field extension so that the effective interaction length exceeds the actual electrode-defined dipole length
Claim 3 gives a quantitative ratio.
3) Two-or-more times enlargement (dependent claim 3)
Dependent claim 3 adds: virtual dipole length is two or more times the actual dipole length. This narrows coverage for a subset of embodiments but may still be relevant for claim charts or litigation positions.
What do the dependent claims add: activation on fluid contact, planar electrodes, integrated circuits, and 2D amplification?
Claim 2: Activated upon contact with target site fluid
This narrows to markers that are responsive upon contact with site fluid (e.g., intestinal fluid). It is not required by claim 1 but may be satisfied in typical ingestible implementations.
Claim 4: Planar electrodes on opposing sides of a solid support
Dependent claim 4 specifies:
- first and second electrodes positioned on opposing sides of a solid support
- solid support positioned between the electrodes
That is a structural packaging constraint likely to be common in thin-film or wafer-like devices.
Claim 5: Solid support comprises an integrated circuit
This ties the solid support to electronics (IC). If competitors embed electrodes around an IC package or use an ASIC/die-based support, they may land within this dependent scope.
Claim 6: Planar electrodes
Further narrows to planar electrodes.
Claim 7: Planar amplification element with outer edge extending beyond electrode edges
The amplification element geometry is constrained:
- planar structure
- outer edge extends beyond the edge of the first/second signal transmission elements
This provides a recognizable design motif: an insulative plate/region larger than the electrode overlap/extent to extend “virtual dipole length.”
Claim 8: 2D signal amplification element
Adds dimensionality: “two-dimensional signal amplification element.” That suggests thin-sheet or planar patterned structures rather than 3D volumes.
Practical infringement implication: even if a competitor uses different electrode geometry or implements non-identical materials, coverage can still be broad as long as it uses an insulative planar amplifier between opposing elements to create a longer virtual dipole.
Does US 8,961,412 cover active agents and signal generation elements beyond the electrodes?
Claim 9: Coupled signal generation element with active agent
Claim 9 adds a payload concept:
- signal generation element coupled to the first and second transmission elements
- an active agent stably associated with the signal generation element
This is significant because it expands the claimed ingestible event marker from purely diagnostic signaling into potentially drug-delivery or therapeutic co-localization contexts (even though the claims you provided do not expressly list the agent class). It also creates additional infringement avenues if competitors use the marker as a combined therapeutic/telemetry platform.
How does claim 10 extend the architecture: third transmission element and multiple dipoles?
Claim 10: Third signal transmission element to make multiple actual dipoles
It permits:
- a third transmission element in opposing spaced relationship to at least one of the first and second transmission elements
- producing a second actual dipole and a third actual dipole
This supports scalability to multi-dipole signaling layouts, likely increasing field coverage or multiplexing.
What about claim 11 and claim 12: explicit definitions and current conduction about the insulative element?
Claim 11: Actual dipole defined between first and second opposing elements
This clarifies how the dipole is defined.
Claim 12: Virtual dipole defined by conducting current between first and second elements about the insulative amplification element
This adds a mechanism-level limitation:
- virtual dipole is defined by conducting electrical current between the first and second signal transmission element
- “about the electrically insulative signal amplification element”
So competitors that do not route current “about” the insulative structure may argue design-around, depending on interpretation of “about” and how fields/currents traverse the geometry.
What does claim 13 add: system coverage with an ingestible marker and a receiver?
Claim 13 is the system claim. It requires:
- ingestible event marker with the same identifier architecture (actual dipole + insulative amplifier producing virtual longer dipole)
- a receiver configured to detect the emitted signal
This matters commercially because system vendors typically sell the receiver infrastructure with ingestible components.
Claims 14-17: in vivo vs external receiver; definition alignment
- Claim 14: receiver is an in vivo receiver
- Claim 15: receiver is an external receiver
- Claim 16: actual dipole definition aligns with claim 11
- Claim 17: virtual dipole definition aligns with claim 12 (current about the insulative amplification element)
Risk coverage: the patent does not constrain whether detection is external or internal, so most telemetry architectures fit.
How do you map this patent to a competitor’s device architecture? (Infringement claim chart logic)
A technical mapping against a generic competitor ingestible event marker should be assessed for these “elements”:
- Two opposing transmission elements: electrodes or signal transmission conductors that act as a dipole pair
- Defined separation / predefined actual dipole length: the physical/electrical configuration yields an identifiable “actual dipole length”
- Insulative amplification element between electrodes: an insulating structure physically located between opposing electrodes
- Virtual dipole longer than actual: design produces an effective length longer than physical dipole
- Current conduction about insulative element: electrical current flows in a way that wraps around or is routed “about” the insulator
- Ingestible activation: signal emitted upon contact with target site and, in narrower dependent scope, upon contact with target site fluid
- Receiver integration: in system-level exposure, any partner receiver that detects the emitted signal completes the system claim
What design-arounds are plausible against this claim set, based on claim language?
Based on the provided claim set, design-arounds cluster around breaking at least one of the required mappings:
-
Eliminate “insulative signal amplification element disposed between”
If the amplification structure is conductive, not disposed between, or not “between” in the claimed geometry, claim 1 may be avoided.
-
Ensure virtual dipole length is not larger than actual dipole length
If the effective/virtual length is equal to or smaller than the actual dipole length, dependent claims also fail.
-
Avoid “current about the electrically insulative amplification element”
If current distribution does not go around the insulative element, claim 12 becomes vulnerable.
-
No ingestible event marker context
If the system is not ingestible or not an “event marker” that emits signal upon contact with a target site, claim 1’s preamble and structure may not match.
-
Avoid system sold with a receiver (for system claims)
Even if marker components infringe claim 1, systems exposure under claim 13 requires a receiver “configured to detect.” But separate component sales might shift exposure to claim 1 (identifier architecture) rather than claim 13.
How does the claim set position the patent vs likely prior art themes?
The claim language indicates it targets problems in dipole-based ingestible telemetry:
- limited effective radiating/interaction distance from small ingestible electronics
- field/near-field coupling inefficiency
- need to increase effective signal interaction length without increasing physical size
The “virtual dipole” framing suggests an approach that extends effective dipole behavior via geometry or field coupling of an insulative structure, rather than by physically enlarging the electrode spacing.
What is missing for an exact US patent landscape map (and therefore cannot be produced here)?
A complete US patent landscape for US 8,961,412 requires:
- the patent’s title, assignee, filing/grant details, and whether it is listed in FDA systems (Orange Book)
- prosecution history, claim dependency variations by prosecution amendments
- the actual specification and drawings to interpret terms like “virtual dipole,” “signal transmission element,” and “about”
- citations to earlier patents and NPL
- current status of related litigations and PTAB proceedings
- the FDA regulatory context (whether any NDA/ANDA lists this in Orange Book)
You asked for “Detailed analysis of the scope and claims and patent landscape for United States Drug Patent 8,961,412,” but only the claim text is available in the prompt. Without bibliographic and legal record data for US 8,961,412, a defensible landscape (other patents, expiry timeline, Paragraph IV posture, inter partes outcomes, and Orange Book status) cannot be compiled to a high standard.
Key Takeaways
- US 8,961,412’s claim core is a two-opposing-element actual dipole paired with an electrically insulative signal amplification element that produces a longer “virtual dipole.”
- The claim set is structured to cover both marker components (claim 1) and complete ingestible telemetry systems (claim 13) including external or in vivo receivers.
- Dependent claims add constraints around fluid-activated signaling, planar electrodes, IC-containing supports, planar/2D amplification geometries, multi-dipole layouts, and current conduction “about” the insulative amplifier.
- Litigation and freedom-to-operate assessments should focus on whether a competitor’s design preserves the required mapping: insulative amplifier between electrodes that creates a longer effective dipole length and routes current about that insulator.
FAQs
-
Does claim 1 require an integrated circuit?
No. An integrated circuit appears only in dependent claim 5 as part of the solid support.
-
Is an external receiver required?
No. Claim 13 covers a system with a receiver generally; dependent claims include both in vivo (claim 14) and external (claim 15).
-
What narrows the “virtual dipole” coverage to high-risk embodiments?
Dependent claim 3’s quantitative limitation (virtual dipole length at least two times the actual dipole length) and claim 12’s “current about the electrically insulative amplification element” mechanism.
-
Can a device with only one dipole pair fall under claim 10?
Claim 10 requires an added third transmission element producing additional actual dipoles, so a single pair would not satisfy claim 10.
-
Does the patent cover ingestible markers tied to drug/therapeutic active agents?
Claim 9 adds an “active agent stably associated” with the signal generation element, but that feature is not required by claim 1.
References
No external sources were provided or available in the prompt beyond the claim text supplied.
